Mantle Cell Lymphoma Study for Transplant-Eligible Patients

ACCRU Trial Spotlight

In ACCRU Study LY1804, principal investigator Dr. Stephen Smith and his team seek to discover whether a high complete response rate can be achieved, including negativity for minimal residual disease. This is a Phase 2 optimization protocol that uses novel agents while reducing chemotheraphy dosing. For more information on the study go here:

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma »